The global radiation oncology market size was valued at USD 9.37 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 12.3% from 2024 to 2030. Key factors driving the market include technological advancement in radiation therapy equipment, global rise in cancer cases, and increasing adoption of radiation therapy in oncology treatment.
Furthermore, the radiation oncology market is witnessing increased demand for radiotherapy due to the rising global cancer burden. According to WHO, globally, around 19.3 million people were suffering from cancer, and 10 million died from it in 2022. Moreover, WHO in Europe estimated that there were 4.6 million new people diagnosed with various indications of cancer such as prostate, breast, lung, colorectal, and brain and around 2.1 million people across European countries died from the disease in 2020. As per American Cancer Society’s 2022 report, breast cancer is most common occurring condition which accounts for around 3 lakh and 51,400 new cases in U.S. of invasive and non-invasive breast tumor, respectively.
In the dynamic market outlook of the radiation therapy space, key players are making strategic moves to enhance their market presence. In October 2023, Accuray Incorporated gained approval for its Tomo C radiation therapy system in China, opening new avenues for growth in the region. This regulatory milestone reflects Accuray's commitment to expanding its market reach. Similarly, in June 2023, PharmaLogic Holdings Corp. entered into a Master Services Agreement for the development and production of theranostic candidates VMT-01 and VMT-NET. These radiopharmaceuticals, currently in the research and development phase, aim to address the diagnostic and treatment needs of metastatic melanoma and neuroendocrine cancers. This strategic collaboration underscores PharmaLogic's dedication to advancing innovative solutions in the oncology space.
Market growth stage is high, and pace of the market growth is accelerating. The radiation therapeutic in oncology is characterized by a high degree of innovation.This can be attributed to advanced technologies and methodologies for transforming treatment practices.The space witnesses a notable M&A activities by the leading players. Leading players are strategically joining forces to expand and enhance their services, gain access to new technologies, consolidate the rapidly growing market, and address increasing strategic importance of radiotherapy.
For instance, in the radiation oncology market, key player IBA has taken a significant step in July 2023 by partnering with Apollo Proton Cancer Centre in India. This collaboration aims to enhance the skills of oncologists in proton beam therapy through specialized training programs. This strategic move by IBA underscores the growing importance of knowledge-sharing and skill development within the radiation oncology sector. The initiative is expected to contribute to the overall advancement of proton therapy applications, potentially impacting the market dynamics positively. As a result, other industry players might consider similar partnerships or training programs to stay competitive and contribute to the overall growth and improvement of radiation oncology practices.
The space is also subject to increasing regulatory scrutiny. Radiation exposure is regulated by governmental agencies such as FDA, Department of Transportation (DOT), Environmental Protection Agency (EPA), and Nuclear Regulatory Commission (NRC). Radiation-emitting devices used in medicine are regulated by Center for Devices and Radiologic Health (CDRH), whereas the use of radiation for medical purposes is regulated by the FDA. Radiation oncology devices are governed under the Radiation Control for Health and Safety Act, 1968.
The Code of Federal Regulations Title 21 governs the use of radiopharmaceuticals in the U.S. The diagnostic and therapeutic applications of radiopharmaceuticals are separately covered under this title in Part 315 & Part 361, respectively. In addition, the Nuclear Regulatory Commission (NRC) regulates the use of radiopharmaceuticals in 37 states. The NRC authorizes utilization and possession of radioactive source material, by product material, and special nuclear material.
CDRH governs the use of radiopharmaceuticals. In addition, it governs use of electron emitting products, including medical devices. However, radioisotopes that produce chemical effects, such as Ra-223, are governed by the Center for Drug Evaluation & Research, and the ones considered biologics, such as I-131 and Y-90, are used for treatment of non-Hodgkin’s lymphoma and are governed by the Center for Biologics Evaluation and Research.
Radiation therapy has significant substitutes like surgeries and chemotherapy that improve many of the anticancer effects but have more side effects. However, any technological advancements in radiation therapy that offer improved technology with high efficacy may be a threat to existing treatment options such IGRT, proton therapy, and 3D-conformity therapy, encouraging patients to shift to advanced treatment options. The lack of effective treatment options for complex cancers and increased side effects of therapies are expected to negatively impact the overall market growth.
Moreover, the industry is witnessing growing number of geographical expansion strategies, for instance, players such as Curium in June 2021, acquired Austrin to expand its presence in Europe for its broad portfolio of life-saving diagnostic solutions. This acquisition will help the company strengthen its positron emission-tomography (PET) radiopharmaceutical business.
The external beam radiation therapy (EBRT) market, which includes linear accelerators (Linac), and compact advanced radiotherapy systems dominated the overall market with the largest share of 62.41% in 2023 due to increased adoption in treatment of various types of cancers. Furthermore, EBRT products has high ability to kill tumor in the early phases as compared to conventional therapies with less side effects. Moreover, rapid technological advancements and investigation of such technologies on various cancer treatment are increasing demand for LINACs and MR-LINACs, thereby, contributing to the growth of radiation oncology markets. For instance, in December 2022, using Elekta Unity MR-Linac, first ever patient got treated for pancreatic tumor with new advanced radiotherapy motion management.
Linear accelerator (Linac) uses microwave technology like radar to destroy tumor cells by delivering high energy electrons or x-rays near tumor region and spare the surrounding healthy tissue. Introduction of novel linear accelerators contributes to market growth. For instance, in September 2020, Elekta AB announced the launch of the Elekta Harmony linear accelerator, which is the productive Linac for the treatment of cancer by radiotherapy. The launch of the new products may contribute to the market growth by addressing the unmet medical needs.
The IMRT segment accounted for the largest share of the radiation oncology market in 2023, attributable to a substantial demand for treatment and increased availability of technologically advanced intensity-modulated radiotherapy (IMRT) in countries with unmet treatment needs. However, brachytherapy is estimated to be the fastest-growing segment over the forecast period due to the benefits associated with its high adoption rate and minimal risk of side effects.
3D-CRT projects radiation beams in such a way that the beams match the dimensions of tumor and help physicians to know the exact dimensions of tumor, which limits the damage to healthy tissues. It allows delivery of higher dose levels at the tumor site, thereby increasing its effectiveness to shrink and destroy the tumor by using a multi-leaf collimeter (MLC) in a step-and-shoot technique. 3D-CRT is used to treat head & neck, liver cancer, prostate, lung, and brain cancer.
The advancements in brachytherapy provide precise and targeted dose delivery and personalized treatment options to patients. This technology is mostly used for the treatment of prostate cancer. Compared to conventional treatment techniques, its improved efficacy and reduced setup time are likely to drive the worldwide brachytherapy segment. Moreover, supportive reimbursement policies for products related to brachytherapy reduced the treatment cost, thereby encouraging patients to avail treatment. In May 2020, Isoray announced the approval of billing codes for reimbursement of Cesium-131 for the hospital in a DRG setting. Cesium-131 is used in brachytherapy to treat various organ tumors.
The EBRT segment accounted for the largest revenue size of radiation oncology market by in 2023 and is anticipated to maintain its dominance over the forecast period. This can be attributed to the rising global cancer prevalence and increasing adoption of EBRT systems by cancer centers and hospitals. For instance, in September 2021, Unicancer acquired multilple Radixact Systems of Accuray, Inc. with the ClearRT with aim to provide personalized treatment patients in Europe. Unicancer is French hospital network that provide treatment to 530,000 cancer patients annually.
The market for IBRT is anticipated to witness significant growth over the forecast period due to growing prevalence of cancer in developing countries, and increased product penetration. IBRT is mostly used in conjunction with breast cancer surgery. Brachytherapy for breast tumor involves different techniques for placing devices such as interstitial brachytherapy and intracavitary brachytherapy. Most performed technique for breast cancer is intracavitary brachytherapy. According to a study published by National Cancer Institute (NCI) showed that whole breast irradiation, (WBI), and accelerated partial-breast irradiation (APBI) lowers the rate for cancer recurring in the breast cancer patients.IMRT has become the standard treatment for locally advanced head & neck cancer due to its high conformality. Moreover, Gynecologic cancer is mostly treated with the help of various brachytherapy techniques.
North America dominated the overall radiation oncology market in terms of revenue share of 45.52% in 2023, owing to the favorable government initiatives and availability of technologically advanced radiotherapy equipment. Furthermore, active participation of key players to increase their market share in region is fueling the market growth. For instance, in December 2022, MVision AI entered partnership with Medron Medical Systems to distribute AI radiotherapy technology of MVision in Canada. The use of AI technology provides high accuracy, leading to improved patient outcomes.
Asia Pacific is estimated to be the fastest-growing region over the forecast period due to improvements in healthcare infrastructure, increase in patient awareness levels, and high unmet patient needs. In addition, rising cancer burden and funding support to major players in the region are expected to offer lucrative opportunity for segment growth. According to Globocan report 2020, about 9.5 million new cancer cases were diagnosed, and 5.8 million died due to this disease in the Asia region, increasing demand for radiotherapy to manage the impact of cancer in the countries.
Some of the key players operating in the industry are Accuray, Inc., Varian Medical Systems, Inc., Ion Beam Application (IBA), Elekta AB,Becton Dickinson and Company, and Isoray Medical. The leading players in radiation oncology industry are focusing on growth strategies, such as innovations with radiotherapy, product launches, and R&D investments. Elekta Ab is geographically expanding in markets outside China and an increasing number of installed units are expected to reach the end of the life cycle, further requiring replacements, service, and support.
RaySearch, VisionRT, Sensus Healthcare are some of the emerging market participants in the radiation oncology space. Emerging companies are employing various strategies such as mergers & acquisitions to expand their footprint and grow at a fast pace.
In October 2023, Accuray incorporated achieved a significant milestone as their Tomo C radiation therapy system gained approval from the Chinese National Medical Products Administration (NMPA). This strategic move by the company reflects its commitment to expanding market presence and catering to the growing demand for advanced radiation oncology solutions in China.
In July 2023, in India IBA took a step towards collaboration by forming a partnership with Apollo Proton Cancer Centre (APCC). The purpose was to offer training sessions for oncologists, focusing on proton beam therapy, demonstrating a commitment to knowledge sharing and professional development within the radiation oncology sector.
In June 2023, PharmaLogic Holdings Corp., a key player in the radiation oncology market, took a significant step by signing a Master Services Agreement. This agreement focuses on the development and production of theranostic candidates VMT-01 and VMT-NET, aiming to address metastatic melanoma and neuroendocrine cancers. Currently, these radiopharmaceuticals are undergoing research and development, highlighting the company's strategic commitment to advancing diagnostic and treatment solutions in the field.
Report Attribute |
Details |
Market size value in 2024 |
USD 10.54 billion |
Revenue forecast in 2030 |
USD 21.14 billion |
Growth rate |
CAGR of 12.3% from 2023 to 2030 |
Actual data |
2018 - 2023 |
Forecast period |
2024 - 2030 |
Quantitative units |
Revenue in USD Billion/Million and CAGR from 2024 to 2030 |
Report coverage |
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
Segments covered |
Type, technology, application, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; U.K.; Germany; France; Spain; Italy; Denmark; Sweden, Norway; Japan; China; India; Australia; South Korea;Thailand Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Key companies profiled |
Varian Medical Systems, Inc.; Elekta AB; Accuray Incorporated; IBA Radiopharma Solutions; BD; Isoray Medical; Mevion Medical Systems, Inc.; Nordion Inc.; NTP Radioisotopes SOC Ltd.; Curium Pharma; Viewray Technologies, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global radiation oncology market report on the basis of type, technology, application, and regions:
Type Outlook (Revenue, USD Million, 2018 - 2030)
External Beam Radiation Therapy
Linear Accelerators (Linac)
Compact advanced radiotherapy systems
Cyberknife
Gamma Knife
Tomotherapy
Proton Therapy
Cyclotron
Synchrotron
Internal Beam Radiation Therapy
Brachytherapy
Seeds
Applicators and After loaders
Electronic Brachytherapy
Systemic Beam Radiation Therapy
Others
Technology Outlook (Revenue, USD Million, 2018 - 2030)
External Beam Radiation Therapy
Image-Guided Radiotherapy (IGRT)
Intensity Modulated Radiotherapy (IMRT)
Stereotactic Technology
Proton Beam Therapy
3D Conformal Radiotherapy (3D CRT)
Volumetric Modulated Arc Therapy (VMAT)
Brachytherapy
Low-Dose Rate Brachytherapy
High-Dose Rate Brachytherapy
Application Outlook (Revenue, USD Million, 2018 - 2030)
External Beam Radiation Therapy
Prostate Cancer
Breast Cancer
Lung Cancer
Head and Neck Cancer
Colorectal Cancer
Others
Internal Beam Radiation Therapy
Prostate Cancer
Gynecological Cancer
Cervical Cancer
Breast Cancer
Penile Cancer
Others
Regional Outlook (Revenue, USD Million; 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Denmark
Sweden
Norway
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
Thailand
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Rest of LATAM
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Rest of MEA
b. The global radiation oncology market size was estimated at USD 8.65 billion in 2022 and is expected to reach USD 9.40 billion in 2023.
b. The global radiation oncology market is expected to witness a compound annual growth rate of 12.3% from 2024 to 2030 to reach USD 21.14 billion in 2030.
b. The IMRT technology segment dominated the market for radiation oncology and accounted for the largest revenue share of 24.5% in 2022. IMRT allows a change in radiation intensity during treatment to specifically target cancer cells and limit the damage to adjoining healthy tissues.
b. Breast cancer treated using EBRT accounted for a significant share in 2022 due to high effectiveness and supporting awareness programs.
b. North America dominated the radiation oncology market in 2022 and accounted for the largest revenue share of more than 44.6%. High healthcare expenditure, advanced healthcare infrastructure, and significant R&D investments are some of the major factors contributing to the market dominance of this region.
b. Based on type, the External Beam Radiation Therapy segment held the largest share of 64.53% in 2022, owing to the relatively higher price of equipment, high installed base, lower side-effects, and ease in delivery as radiologists can control the rate of radiotherapy.
Table of Contents
Chapter 1 Radiation Oncology Market: Methodology And Scope
1.1 Market Segmentation And Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline:
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 List Of Secondary Sources
1.8 List Of Abbreviations
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.9.3 Objective 3
1.9.4 Objective 4
Chapter 2 Radiation Oncology Market: Executive Summary
2.1 Market Summary
Chapter 3 Radiation Oncology Market: Variables, Trends & Scope
3.1 Market Segmentation
3.2 Market Definitions
3.3 Key Opportunities Prioritized
3.4 Market Dynamic Analysis
3.4.1 Rising Adoption Of Radiotherapy
3.4.2 Technological Advancements In Radiotherapy
3.4.3 Rising Prevalence Of Cancer
3.4.4 Increase In Healthcare Expenditure
3.4.5 Increasing APPLICATION OF Radiopharmaceuticals
3.5 Market Restraint Analysis
3.5.1 Lack Of Skilled Radiotherapy Professionals
3.5.2 Inadequate Radiation Infrastructure
3.5.3 Adverse Effects Of Radiotherapy
3.6 Business Environment Analysis
3.6.1 SWOT Analysis; By Factor (POLITICAL & LEGAL, Economic And Technological)
3.6.2 Porter’s Five Forces Analysis
Chapter 4 Radiation Oncology Market - Segment Analysis, By Type, 2018 - 2030 (USD Million)
4.1 Radiation Oncology Market: Type Movement Analysis
4.2 External Beam Radiation Therapy
4.2.1 External Beam Radiation Therapy Market, 2018 - 2030 (USD Million)
4.2.2 Electron-Emitting High Energy Linear Accelerators
4.2.2.1 Electron-Emitting High Energy Linear Accelerators Market, 2018 - 2030 (USD Million)
4.2.3 Compact Advanced Radiotherapy Systems
4.2.3.1 Compact Advanced Radiotherapy Systems Market, 2018 - 2030 (USD Million)
4.2.3.2 Cyberknife
4.2.3.2.1 Cyberknife Market, 2018 - 2030 (USD Million)
4.2.3.3 Gamma Knife
4.2.3.3.1 Gamma Knife Market, 2018 - 2030 (USD Million)
4.2.3.4 Tomotherapy
4.2.3.4.1 Tomotherapy Compact Market, 2018 - 2030 (USD Million)
4.2.4 Proton Therapy
4.2.4.1 Proton Therapy Market, 2018 - 2030 (USD Million)
4.2.4.2 Cyclotron
4.2.4.2.1 Cyclotron Market, 2018 - 2030 (USD Million)
4.2.4.3 Synchrotron
4.2.4.3.1 Synchrotron Market, 2018 - 2030 (USD Million)
4.3 Internal Beam Radiation Therapy
4.3.1 Internal Beam Radiation Therapy Market, 2018 - 2030 (USD Million)
4.3.2 Brachytherapy
4.3.2.1 Brachytherapy Market, 2018 - 2030 (USD Million)
4.3.2.2 Seeds
4.3.2.2.1 Seeds Market, 2018 - 2030 (USD Million)
4.3.2.3 Applicators And After-Loaders
4.3.2.3.1 Applicators And After-Loaders Market, 2018 - 2030 (USD Million)
4.3.2.4 Electronic Brachytherapy
4.3.2.4.1 Electronic Brachytherapy Market, 2018 - 2030 (USD Million)
4.3.3 Systemic Beam Radiation Therapy
4.3.3.1 Systemic Beam Radiation Therapy Market, 2018 - 2030 (USD Million)
4.3.4 Others
4.3.4.1 Others Market, 2016-2028 (USD Million)
Chapter 5 Radiation Oncology Market - Segment Analysis, By Technology, 2018 - 2030 (USD Million)
5.1 Radiation Oncology Market: Technology Movement Analysis
5.2 External Beam Radiation Therapy (EBRT)
5.2.1 EBRT Market, 2018 - 2030 (USD Million)
5.2.2 Image-Guided Radiation Therapy (IGRT)
5.2.2.1 IGRT Market, 2018 - 2030 (USD Million) (Procedure Volume)
5.2.3 Intensity Modulated Radiotherapy (IMRT)
5.2.3.1 IMRT Market, 2018 - 2030 (USD Million) (Procedure Volume)
5.2.4 Stereotactic Radiotherapy
5.2.4.1 Stereotactic Radiotherapy Market, 2018 - 2030 (USD Million) (Procedure Volume)
5.2.5 Proton Beam Therapy
5.2.5.1 Proton Beam Therapy Market, 2018 - 2030 (USD Million) (Procedure Volume)
5.2.6 3D Conformal Radiotherapy (3D-CRT)
5.2.6.1 3D-CRT Market, 2018 - 2030 (USD Million) (Procedure Volume)
5.2.7 Volumetric Modulated Arc Therapy (VMAT)
5.2.7.1 VMAT Market, 2018 - 2030 (USD Million) (Procedure Volume)
5.3 Brachytherapy
5.3.1 Brachytherapy Market, 2018 - 2030 (USD Million)
5.3.2 Low Dose Rate (LDR) Brachytherapy
5.3.2.1 LDR Brachytherapy Market, 2018 - 2030 (USD Million)
5.3.3 High Dose Rate (HDR) Brachytherapy
5.3.3.1 HDR Brachytherapy Market, 2018 - 2030 (USD Million)
Chapter 6 Radiation Oncology Market - Segment Analysis, By Application, 2018 - 2030 (USD Million)
6.1 Radiation Oncology Market: Application Movement Analysis
6.2 External Beam Radiation Therapy (EBRT)
6.2.1 Prostate Cancer
6.2.1.1 Prostate Cancer Market, 2018 - 2030 (USD Million)
6.2.2 Breast Cancer
6.2.2.1 Breast Cancer Market, 2018 - 2030 (USD Million)
6.2.3 Lung Cancer
6.2.3.1 Lung Cancer Market, 2018 - 2030 (USD Million)
6.2.4 Head And Neck Cancer
6.2.4.1 Head And Neck Cancer Market, 2018 - 2030 (USD Million)
6.2.5 Colorectal Cancer
6.2.5.1 Colorectal Cancer Market, 2018 - 2030 (USD Million)
6.2.6 Others
6.2.6.1 Others Market, 2018 - 2030 (USD Million)
6.3 Internal Beam Radiation Therapy
6.3.1 Prostate Cancer
6.3.1.1 Prostate Cancer Market, 2018 - 2030 (USD Million)
6.3.2 Gynecologic Cancer
6.3.2.1 Gynecologic Cancer Market, 2018 - 2030 (USD Million)
6.3.3 Breast Cancer
6.3.3.1 Breast Cancer Market, 2018 - 2030 (USD Million)
6.3.4 Cervical Cancer
6.3.4.1 Cervical Cancer Market, 2018 - 2030 (USD Million)
6.3.5 Penile Cancer
6.3.5.1 Penile Cancer Market, 2018 - 2030 (USD Million)
6.3.6 Others
6.3.6.1 Others Market, 2018 - 2030 (USD Million)
Chapter 7 Radiation Oncology Market - Segment Analysis, By Region, 2018 - 2030 (USD Million)
7.1 Definition & Scope
7.2 North America
7.2.1 North America, SWOT Analysis
7.2.2 U.S.
7.2.2.1 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.2.2.2 Key Country Dynamics
7.2.2.3 Target Disease Prevalence
7.2.2.4 Competitive Scenario
7.2.2.5 Regulatory Framework
7.2.2.6 Reimbursement Scenario
7.2.3 Canada
7.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.2.3.2 Key Country Dynamics
7.2.3.3 Target Disease Prevalence
7.2.3.4 Competitive Scenario
7.2.3.5 Regulatory Framework
7.2.3.6 Reimbursement Scenario
7.3 Europe
7.3.1 Europe, SWOT Analysis
7.3.2 U.K.
7.3.2.1 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.2.2 Key Country Dynamics
7.3.2.3 Target Disease Prevalence
7.3.2.4 Competitive Scenario
7.3.2.5 Regulatory Framework
7.3.2.6 Reimbursement Scenario
7.3.3 Germany
7.3.3.1 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.3.2 Key Country Dynamics
7.3.3.3 Target Disease Prevalence
7.3.3.4 Competitive Scenario
7.3.3.5 Regulatory Framework
7.3.3.6 Reimbursement Scenario
7.3.4 France
7.3.4.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.4.2 Key Country Dynamics
7.3.4.3 Target Disease Prevalence
7.3.4.4 Competitive Scenario
7.3.4.5 Regulatory Framework
7.3.4.6 Reimbursement Scenario
7.3.5 Italy
7.3.5.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.5.2 Key Country Dynamics
7.3.5.3 Target Disease Prevalence
7.3.5.4 Competitive Scenario
7.3.5.5 Regulatory Framework
7.3.5.6 Reimbursement Scenario
7.3.6 Spain
7.3.6.1 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.6.2 Key Country Dynamics
7.3.6.3 Target Disease Prevalence
7.3.6.4 Competitive Scenario
7.3.6.5 Regulatory Framework
7.3.6.6 Reimbursement Scenario
7.3.7 Sweden
7.3.7.1 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.7.2 Key Country Dynamics
7.3.7.3 Target Disease Prevalence
7.3.7.4 Competitive Scenario
7.3.7.5 Regulatory Framework
7.3.7.6 Reimbursement Scenario
7.3.8 Denmark
7.3.8.1 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.8.2 Key Country Dynamics
7.3.8.3 Target Disease Prevalence
7.3.8.4 Competitive Scenario
7.3.8.5 Regulatory Framework
7.3.8.6 Reimbursement Scenario
7.3.9 Norway
7.3.9.1 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.9.2 Key Country Dynamics
7.3.9.3 Target Disease Prevalence
7.3.9.4 Competitive Scenario
7.3.9.5 Regulatory Framework
7.3.9.6 Reimbursement Scenario
7.3.10 Rest Of Europe
7.3.10.1 Rest Of Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific, SWOT Analysis
7.4.2 India
7.4.2.1 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.2.2 Key Country Dynamics
7.4.2.3 Target Disease Prevalence
7.4.2.4 Competitive Scenario
7.4.2.5 Regulatory Framework
7.4.2.6 Reimbursement Scenario
7.4.3 China
7.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.3.2 Key Country Dynamics
7.4.3.3 Target Disease Prevalence
7.4.3.4 Competitive Scenario
7.4.3.5 Regulatory Framework
7.4.3.6 Reimbursement Scenario
7.4.4 Japan
7.4.4.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.4.2 Key Country Dynamics
7.4.4.3 Target Disease Prevalence
7.4.4.4 Competitive Scenario
7.4.4.5 Regulatory Framework
7.4.4.6 Reimbursement Scenario
7.4.5 Australia
7.4.5.1 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.5.2 Key Country Dynamics
7.4.5.3 Target Disease Prevalence
7.4.5.4 Competitive Scenario
7.4.5.5 Regulatory Framework
7.4.5.6 Reimbursement Scenario
7.4.6 South Korea
7.4.6.1 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.6.2 Key Country Dynamics
7.4.6.3 Target Disease Prevalence
7.4.6.4 Competitive Scenario
7.4.6.5 Regulatory Framework
7.4.6.6 Reimbursement Scenario
7.4.7 THAILAND
7.4.7.1 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.7.2 Key Country Dynamics
7.4.7.3 Target Disease Prevalence
7.4.7.4 Competitive Scenario
7.4.7.5 Regulatory Framework
7.4.7.6 Reimbursement Scenario
7.4.8 Rest Of APAC
7.4.8.1 Rest Of APAC Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America, SWOT Analysis
7.5.2 Mexico
7.5.2.1 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.5.2.2 Key Country Dynamics
7.5.2.3 Target Disease Prevalence
7.5.2.4 Competitive Scenario
7.5.2.5 Regulatory Framework
7.5.2.6 Reimbursement Scenario
7.5.3 Brazil
7.5.3.1 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.5.3.2 Key Country Dynamics
7.5.3.3 Target Disease Prevalence
7.5.3.4 Competitive Scenario
7.5.3.5 Regulatory Framework
7.5.3.6 Reimbursement Scenario
7.5.4 Argentina
7.5.4.1 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.5.4.2 Key Country Dynamics
7.5.4.3 Target Disease Prevalence
7.5.4.4 Competitive Scenario
7.5.4.5 Regulatory Framework
7.5.4.6 Reimbursement Scenario
7.5.5 Rest Of LATAM
7.5.5.1 Rest Of LATAM Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6 MEA
7.6.1 Middle East & Africa, SWOT Analysis
7.6.2 South Africa
7.6.2.1 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6.2.2 Key Country Dynamics
7.6.2.3 Target Disease Prevalence
7.6.2.4 Competitive Scenario
7.6.2.5 Regulatory Framework
7.6.2.6 Reimbursement Scenario
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6.3.2 Key Country Dynamics
7.6.3.3 Target Disease Prevalence
7.6.3.4 Competitive Scenario
7.6.3.5 Regulatory Framework
7.6.3.6 Reimbursement Scenario
7.6.4 UAE
7.6.4.1 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6.4.2 Key Country Dynamics
7.6.4.3 Target Disease Prevalence
7.6.4.4 Competitive Scenario
7.6.4.5 Regulatory Framework
7.6.4.6 Reimbursement Scenario
7.6.5 Kuwait
7.6.5.1 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6.5.2 Key Country Dynamics
7.6.5.3 Target Disease Prevalence
7.6.5.4 Competitive Scenario
7.6.5.5 Regulatory Framework
7.6.5.6 Reimbursement Scenario
7.6.6 Rest Of MEA
7.6.6.1 Rest Of MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 8 Competitive Landscape
8.1 Public Companies
8.1.1 Company Market Position Analysis
8.1.2 Competitive Dashboard Analysis
8.1.3 Strategic Framework
8.2 Private Companies
8.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
8.2.2 Regional Network Map
8.3 Company Profiles
8.3.1 Varian Medical Systems, Inc. (A Part Of Siemens Healthineers)
8.3.1.1 Company Overview
8.3.1.2 Financial Performance
8.3.1.3 Product Benchmarking
8.3.1.4 Strategic Initiatives
8.3.2 Elekta AB
8.3.2.1 Company Overview
8.3.2.2 Financial Performance
8.3.2.3 Product Benchmarking
8.3.2.4 Strategic Initiatives
8.3.3 Accuray Incorporated
8.3.3.1 Company Overview
8.3.3.2 Financial Performance
8.3.3.3 Product Benchmarking
8.3.3.4 Strategic Initiatives
8.3.4 Ion Beam Applications (IBA).
8.3.4.1 Company Overview
8.3.4.2 Financial Performance
8.3.4.3 Product Benchmarking
8.3.4.4 Strategic Initiatives
8.3.5 BD (Becton, Dickinson And Company)
8.3.5.1 Company Overview
8.3.5.2 Financial Performance
8.3.5.3 Product Benchmarking
8.3.5.4 Strategic Initiatives
8.3.6 Isoray Medical
8.3.6.1 Company Overview
8.3.6.2 Financial Performance
8.3.6.3 Product Benchmarking
8.3.6.4 Strategic Initiatives
8.3.7 Mevion Medical Systems
8.3.7.1 Company Overview
8.3.7.2 Product Benchmarking
8.3.7.3 Strategic Initiatives
8.3.8 Nordion Inc.
8.3.8.1 Company Overview
8.3.8.2 Product Benchmarking
8.3.8.3 Strategic Initiatives
8.3.9 NTP Radioisotopes SOC Ltd.
8.3.9.1 Company Overview
8.3.9.2 Financial Performance
8.3.9.3 Product Benchmarking
8.3.9.4 Strategic Initiatives
8.3.10 Curium
8.3.10.1 Company Overview
8.3.10.2 Product Benchmarking
8.3.10.3 Strategic Initiatives
8.3.11 VIEWRAY TECHNOLOGIES, INC.
8.3.11.1 Company Overview
8.3.11.2 Financial Performance
8.3.11.3 Product Benchmarking
8.3.11.4 Strategic Initiatives
8.5 External Beam Radiation Therapy, Company Market Share Analysis, 2023, By Region
8.5.1 North America
8.5.2 Europe
8.5.3 Asia Pacific
8.5.4 Latin America
8.5.5 MEA
8.6 LINACs, Company Market Share Analysis, 2023, By Region
8.6.1 North America
8.6.2 Europe
8.6.3 Asia Pacific
8.6.4 Latin America
8.6.5 MEA
8.7 Internal Beam Radiation Therapy, Company Market Share Analysis, 2023, By Region
8.7.1 North America
8.7.2 Europe
8.7.3 Asia Pacific
8.7.4 Latin America
8.7.5 MEA
8.8 Brachytherapy, Company Market Share Analysis, 2023, By Region
8.8.1 North America
8.8.2 Europe
8.8.3 Asia Pacific
8.8.4 Latin America
8.8.5 MEA
Chapter 9 Conclusion
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 List of Parameters
Table 4 List of Distributors
Table 5 Global Radiation Oncology Market, By Region, 2018 - 2030 (USD Million)
Table 6 Global Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 7 Global Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 8 Global Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 9 North America Radiation Oncology Market, By Country, 2018 - 2030 (USD Million)
Table 10 North America Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 11 North America Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 12 North America Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 13 U.S. Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 14 U.S. Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 15 U.S. Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 16 Canada Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 17 Canada Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 18 Canada Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 19 Europe Radiation Oncology Market, By Country, 2018 - 2030 (USD Million)
Table 20 Europe Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 21 Europe Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 22 Europe Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 23 Germany Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 24 Germany Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 25 Germany Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 26 U.K. Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 27 U.K. Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 28 U.K. Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 29 France Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 30 France Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 31 France Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 32 Italy Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 33 Italy Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 34 Italy Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 35 Spain Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 36 Spain Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 37 Spain Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 38 Denmark Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 39 Denmark Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 40 Denmark Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 41 Sweden Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 42 Sweden Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 43 Sweden Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 44 Norway Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 45 Norway Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 46 Norway Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 47 Asia Pacific Radiation Oncology Market, By Country, 2018 - 2030 (USD Million)
Table 48 Asia Pacific Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 49 Asia Pacific Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 50 Asia Pacific Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 51 Japan Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 52 Japan Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 53 Japan Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 54 China Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 55 China Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 56 China Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 57 India Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 58 India Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 59 India Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 60 South Korea Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 61 South Korea Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 62 South Korea Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 63 Australia Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 64 Australia Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 65 Australia Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 66 Thailand Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 67 Thailand Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 68 Thailand Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 69 Latin America Radiation Oncology Market, By Country, 2018 - 2030 (USD Million)
Table 70 Latin America Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 71 Latin America Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 72 Latin America Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 73 Brazil Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 74 Brazil Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 75 Brazil Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 76 Mexico Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 77 Mexico Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 78 Mexico Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 79 Argentina Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 80 Argentina Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 81 Argentina Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 82 Middle East & Africa Radiation Oncology Market, By Country, 2018 - 2030 (USD Million)
Table 83 Middle East & Africa Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 84 Middle East & Africa Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 85 Middle East & Africa Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 86 Saudi Arabia Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 89 South Africa Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 90 South Africa Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 91 South Africa Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 92 UAE Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 93 UAE Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 94 UAE Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
Table 95 Kuwait Radiation Oncology Market, By Type, 2018 - 2030 (USD Million)
Table 96 Kuwait Radiation Oncology Market, By Technology, 2018 - 2030 (USD Million)
Table 97 Kuwait Radiation Oncology Market, By Application, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Radiation oncology market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Radiation oncology market snapshot
Fig. 10 Radiation oncology market segmentation
Fig. 11 Radiation oncology market driver impact
Fig. 12 Radiation oncology market restraint impact
Fig. 13 Key market opportunities
Fig. 14 SWOT analysis, by factor (political & legal economic and technological)
Fig. 15 Porter’s five forces analysis
Fig. 16 Radiation oncology market: Type outlook and key takeaways
Fig. 17 Radiation oncology market: Type movement analysis
Fig. 18 External beam radiation therapy market, 2018 - 2030 (USD Million)
Fig. 19 Electron-emitting high energy linear accelerators market, 2018 - 2030 (USD Million)
Fig. 20 Compact advanced radiotherapy systems market, 2018 - 2030 (USD Million)
Fig. 21 CyberKnife market, 2018 - 2030 (USD Million)
Fig. 22 Gamma Knife market, 2018 - 2030 (USD Million)
Fig. 23 Tomotherapy market, 2018 - 2030 (USD Million)
Fig. 24 Proton therapy market, 2018 - 2030 (USD Million)
Fig. 25 Cyclotron market, 2018 - 2030 (USD Million)
Fig. 26 Synchrotron market, 2018 - 2030 (USD Million)
Fig. 27 Internal beam radiation therapy market, 2018 - 2030 (USD Million)
Fig. 28 Brachytherapy market, 2018 - 2030 (USD Million)
Fig. 29 Seeds market, 2018 - 2030 (USD Million)
Fig. 30 Applicators and after-loaders market, 2018 - 2030 (USD Million)
Fig. 31 Electronic brachytherapy market, 2018 - 2030 (USD Million)
Fig. 32 Systemic beam radiation therapy market, 2018 - 2030 (USD Million)
Fig. 33 Others market, 2016–2028 (USD Million)
Fig. 34 Radiation oncology market: External Beam Radiation Therapy (EBRT) technology outlook and key takeaways
Fig. 35 Radiation oncology market: External Beam Radiation Therapy (EBRT) technology movement analysis
Fig. 36 Radiation oncology market: Internal Beam Radiation Therapy (IBRT) technology movement analysis
Fig. 37 EBRT market, 2018 - 2030 (USD Million)
Fig. 38 IGRT market, 2018 - 2030 (USD Million)
Fig. 39 IMRT market, 2018 - 2030 (USD Million)
Fig. 40 Stereotactic radiotherapy market, 2018 - 2030 (USD Million)
Fig. 41 Proton beam therapy market, 2018 - 2030 (USD Million)
Fig. 42 3D-CRT market, 2018 - 2030 (USD Million)
Fig. 43 VMAT market, 2018 - 2030 (USD Million)
Fig. 44 Brachytherapy market, 2018 - 2030 (USD Million)
Fig. 45 LDR brachytherapy market, 2018 - 2030 (USD Million)
Fig. 46 HDR brachytherapy market, 2018 - 2030 (USD Million)
Fig. 47 Radiation oncology market: Application outlook and key takeaways
Fig. 48 Radiation oncology market: EBRT Application movement analysis
Fig. 49 Prostate cancer market, 2018 - 2030 (USD Million)
Fig. 50 Breast cancer market, 2018 - 2030 (USD Million)
Fig. 51 Lung cancer market, 2018 - 2030 (USD Million)
Fig. 52 Head and neck cancer market, 2018 - 2030 (USD Million)
Fig. 53 Colorectal cancer market, 2018 - 2030 (USD Million)
Fig. 54 Others market, 2018 - 2030 (USD Million)
Fig. 55 Prostate cancer market, 2018 - 2030 (USD Million)
Fig. 56 Gynecologic cancer market, 2018 - 2030 (USD Million)
Fig. 57 Breast cancer market, 2018 - 2030 (USD Million)
Fig. 58 Cervical cancer market, 2018 - 2030 (USD Million)
Fig. 59 Penile cancer market, 2018 - 2030 (USD Million)
Fig. 60 Others market, 2018 - 2030 (USD Million)
Fig. 61 Radiation Oncology market: Regional outlook and key takeaways
Fig. 62 Radiation Oncology Market: Regional Movement Analysis
Fig. 63 North America
Fig. 64 North America radiation oncology market estimates and forecast, 2018 - 2030
Fig. 65 U.S.
Fig. 66 U.S. radiation oncology market estimates and forecast, 2018 - 2030
Fig. 67 Canada
Fig. 68 Canada radiation oncology market estimates and forecast, 2018 - 2030
Fig. 69 Europe
Fig. 70 Europe radiation oncology market estimates and forecast, 2018 - 2030
Fig. 71 Germany
Fig. 72 Germany radiation oncology market estimates and forecast, 2018 - 2030
Fig. 73 U.K.
Fig. 74 U.K. radiation oncology market estimates and forecast, 2018 - 2030
Fig. 75 France
Fig. 76 France radiation oncology market estimates and forecast, 2018 - 2030
Fig. 77 Italy
Fig. 78 Italy radiation oncology market estimates and forecast, 2018 - 2030
Fig. 79 Spain
Fig. 80 Spain radiation oncology market estimates and forecast, 2018 - 2030
Fig. 81 Denmark
Fig. 82 Denmark radiation oncology Market, 2018 - 2030 (USD Million)
Fig. 83 Sweden
Fig. 84 Sweden radiation oncology Market, 2018 - 2030 (USD Million)
Fig. 85 Norway
Fig. 86 Norway radiation oncology Market, 2018 - 2030 (USD Million)
Fig. 87 Rest of Europe
Fig. 88 Rest of Europe radiation oncology Market, 2018 - 2030 (USD Million
Fig. 89 Asia Pacific
Fig. 90 Asia Pacific radiation oncology market estimates and forecast, 2018 - 2030
Fig. 91 Japan
Fig. 92 Japan radiation oncology market estimates and forecast, 2018 - 2030
Fig. 93 China
Fig. 94 China radiation oncology market estimates and forecast, 2018 - 2030
Fig. 95 India
Fig. 96 India radiation oncology market estimates and forecast, 2018 - 2030
Fig. 97 South Korea
Fig. 98 South Korea radiation oncology market estimates and forecast, 2018 - 2030
Fig. 99 Australia
Fig. 100 Australia radiation oncology market estimates and forecast, 2018 - 2030
Fig. 101 Thailand
Fig. 102 Thailand radiation oncology Market, 2018 - 2030 (USD Million)
Fig. 103 Rest of APAC
Fig. 104 Rest of APAC radiation oncology Market, 2018 - 2030 (USD Million)
Fig. 105 Latin America
Fig. 106 Latin America radiation oncology market estimates and forecast, 2018 - 2030
Fig. 107 Brazil
Fig. 108 Brazil radiation oncology market estimates and forecast, 2018 - 2030
Fig. 109 Mexico
Fig. 110 Mexico radiation oncology market estimates and forecast, 2018 - 2030
Fig. 111 Argentina
Fig. 112 Argentina radiation oncology market estimates and forecast, 2018 - 2030
Fig. 113 Rest of LATAM
Fig. 114 Rest of LATAM radiation oncology Market, 2018 - 2030 (USD Million)
Fig. 115 Middle East & Africa
Fig. 116 Middle East and Africa radiation oncology market estimates and forecast, 2018 - 2030
Fig. 117 South Africa
Fig. 118 South Africa radiation oncology market estimates and forecast, 2018 - 2030
Fig. 119 Saudi Arabia
Fig. 120 Saudi Arabia radiation oncology market estimates and forecast, 2018 - 2030
Fig. 121 UAE
Fig. 122 UAE radiation oncology market estimates and forecast, 2018 - 2030
Fig. 123 Kuwait
Fig. 124 Kuwait radiation oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 125 Rest of MEA
Fig. 126 Rest of MEA radiation oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 127 Company market share analysis
Fig. 128 Company market position analysis (Total revenue)
Fig. 129 Company market position analysis (Profit margin)
Fig. 130 Competitive dashboard analysis
Fig. 131 Regional Network Map
Fig. 132 Strategic Framework
Market Segmentation
Radiation therapy can be used for prophylactic, curative, or palliative treatment and is used in immunotherapy, chemotherapy, and in combination with surgeries. Physicians have been adopting radiotherapy due to its wide range of applications. According to an article published in Seminars in Radiation Oncology, in 2017, it was estimated that more than 12,000 additional treatment machines will be required by 2035 in low- and middle-income countries alone. For example, by 2035, China, India, and Brazil are estimated to require over 3,800, 1,200, and 400 additional machines, respectively. The adoption rate is significantly increasing in the developing countries of Asia Pacific. For instance, in 2015, there were 363 centers (301 linear accelerators, 247 brachytherapy systems and 228 Cobalt 60 units) providing radiotherapy treatment in India, which has grown to 545 tele therapy machines (180 tele cobalt units and 365 medical accelerators) in 2019.
The latest advancements in radiation therapy allow delivery of a high amount of dose to the target area without any damage to nearby healthy tissues. This has increased the chances of localized tumor control and has improved cure rates, leading to an increase in demand for radiation therapy. Some radiation therapies such as Low-Dose Rate (LDR) brachytherapy or CyberKnife do not require hospitalization and duration of treatment procedures is also less. According to the European Society for Therapeutic Radiation and Oncology (ESTRO) 2017, High-Dose Rate (HDR) brachytherapy provides high patient satisfaction. Radiation oncologists are increasingly adopting Intensity Modulated Radiation Therapy (IMRT) due to its ability to deliver conformal dose and reduce dose exposure to the surrounding normal tissues. The combination of radiation therapy and chemotherapy has become standard for treating solid tumors at an intermediate stage. This has led to the delivery of low doses of each modality without compromising on treatment efficiency. The combination of imaging with radiotherapy is also gaining popularity among physicians due to its ability to provide powerful imaging techniques along with radiation therapy.
As per the International Agency for Research on Cancer, in 2018, an estimated 18.1 million people were suffering from cancer worldwide. This number is expected to rise to 24 million by 2035. It is also estimated that 23.6 million new cancer cases will be reported by 2030. In 2018, cancer accounted for an estimated 9.6 million deaths. According to WHO’s Cancer Facts, female breast cancer, prostate cancer, lung cancer, and bowel cancer are the most commonly prevalent cancers globally. Lung cancer is the most common cause of death with almost 1.8 million, i.e., 18.4% of total deaths being due to lung cancer in 2018.
Aging is the most common factor that increases the risk of cancer. According to Cancer Research UK, between 2014-2016, on an average each year, more than a third of new cases were reported by people aged 75 and over. The second most common risk factor for cancer is tobacco consumption. As per Cancer Research UK in 2018, around 15% of cancer deaths in the UK are due to tobacco smoking. The next major risk factor is obesity, with the American Society of Clinical Oncology (ASCO) stating that obesity may surpass tobacco as the largest cause of cancer. Certain factors, such as alcohol consumption, improper diet, and lack of exercise, also cause cancer. It was estimated by Cancer Research UK that as of 2018, around 42% of cancer cases in the UK were associated with a combination of lifestyle and other factors, and 135,000 cancer cases are preventable if a healthy lifestyle is adopted.
The rise in cancer prevalence has led to an increase in the demand for radiation therapy. According to an article published in the Indian Journal of Cancer in 2019, the Directory of Radiotherapy Centers (DIRAC) of IAEA has listed India along with the poorest sub-Saharan African countries, in terms of holding less than one radiotherapy machine per million people. Moreover, approximately 50% of patients with cancer that require radiotherapy in LMIC (Low- or Middle-Income Country) lack access to treatment. The condition is even worse in low-income countries, where the share is higher than 90%. As per Cancer Atlas, 82% of the world’s population in developing nations is unable to access radiotherapy. In low- and middle-income countries, inadequate access to reasonable & quality cancer care has led to 20% higher mortality rate as compared to industrialized nations. Thus, majority of cancer patients have no access to radiotherapy treatment. Low- and middle-income countries have a severe disadvantage due to the increasing demand and supply gap of radiotherapy machines. Africa and Southeast Asia are facing considerable shortages of teletherapy units, with nearly 30 countries being deprived of radiation therapy services. However, increase in healthcare expenditure in developing countries is expected to aid in overcoming these challenges.
This section will provide insights into the contents included in this radiation oncology market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.
Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
Company overview
Financial performance
Product benchmarking
Latest strategic developments
Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance
A three-pronged approach was followed for deducing the radiation oncology market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:
Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for radiation oncology market to gather the most reliable and current information possible.
Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of radiation oncology market data depending on the type of information we’re trying to uncover in our research.
Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.
Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.
Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.
Qualitative Functional Deployment (QFD) Modelling for market share assessment.
Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.
Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.
Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.
This step also entails the finalization of the report scope and data representation pattern.
Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.
The radiation oncology market was categorized into four segments, namely type (External Beam Radiation Therapy, Internal Beam Radiation Therapy), technology (External Beam Radiation Therapy, Brachytherapy), application (External Beam Radiation Therapy, Internal Beam Radiation Therapy), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)
The radiation oncology market was segmented into type, technology, application, and region. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:
Demand estimation of each product across countries/regions summed up to from the total market.
Variable analysis for demand forecast.
Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.
Primary interviews for data revalidation and insight collection.
Used extensively for new product forecasting or analyzing penetration levels.
Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.
Primary interviews and vendor-based primary research for variable impact analysis.
The radiation oncology market was analyzed at a regional level. The globe was divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into twenty-three countries, namely, the U.S.; Canada; the UK; Germany; France; Spain; Italy; Denmark; Sweden, Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait.
All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.
The radiation oncology market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:
Varian Medical Systems, Inc. is headquartered in the U.S. It offers products and solutions for cancer treatment. The company develops software and systems that harness X-ray energy to provide advanced radiotherapy, brachytherapy, proton therapy, and radiosurgery. These advanced therapies enable healthcare professionals to efficiently treat cancer patients. The company also provides non-destructive testing, cargo screening, X-ray tube technology, and digital image detectors. The company’s facilities are located in Singapore, India, Hong Kong, Netherlands, Japan, Malaysia, the UK, Belgium, Germany, Brazil, Austria, Finland, Australia, France, Saudi Arabia, Spain, the U.S., Canada, Switzerland, United Arab Emirates, China, and Italy. The company partners with healthcare professionals to provide complete care to cancer patients.
Elekta AB was incorporated in 1972 and is headquartered in Sweden. It offers solutions and informatics for treating cancer. It develops equipment and software that aid cancer and brain disorder patients with an aim to improve, save, and prolong their lives. The company has presence in the Americas, Europe, Middle East & Africa, and Asia Pacific regions. The company offers cost-effective products & solutions to enhance the delivery of brachytherapy, radiosurgery, and radiation therapy. Elekta has pioneered the stereotactic radiosurgery and is a world leader in the field of brachytherapy.
Accuray Incorporated offers a wide range of products and services for radiation therapy and radiosurgery. The company develops, manufactures, and sells precise and innovative solutions for radiation therapy. Moreover, it offers a wide portfolio of radiosurgery and radiation therapy platforms to treat various forms of cancer. The company was incorporated in 1990 and began its commercial operations in 1992. It is headquartered in the U.S. and has its international headquarters in Switzerland. The company is also present in France, Japan, Hong Kong, and China.
Ion Beam Application is Belgium-based company catering to medical devices market. It was established in 1986 and has presence in North & South America, Europe, and Asia. The company invents and manufactures medical devices and supports software solutions for the treatment of cancer. The company collaborates with various healthcare leaders and academic health centers to provide a complete integrated approach for patients. The company specializes in proton therapy technologies and is a worldwide leader in advanced cancer radiation therapy. Additionally, the company provides equipment and software that allows clinics to perform vital calibration and checks required during radiation therapy. It also provides particle accelerators required for the production of radioisotopes during cancer treatments.
Becton, Dickinson and Company was incorporated in 1897 and is headquartered in the US. It is a medical technology company that serves clinical laboratories, life sciences researchers, and healthcare institutions & industries. The company manufactures and markets a wide range of devices, diagnostic products, medical supplies, and laboratory equipment. The company operates across 3 business segments: BD Diagnostics, BD Medical, and BD Biosciences. Its brachytherapy business was acquired from C.R. Bards. C. R. Bard, Inc. develops, manufactures, and sells medical devices. The company introduced single patient use medical products for hospitals. It develops and markets innovative medical technologies in fields of oncology, vascular studies, urology, and surgical products. The company is located in the U.S., Asia Pacific, Australia, Austria, Belgium, Canada, Denmark, England, Finland, France, Germany, Greece, Italy, Japan, Netherlands, Norway, Portugal, South Africa, Spain, and Sweden.
Isoray Medical designs and developed customized brachytherapy products, which are capable of treating a wide range of cancers. The company was founded in 1998 and is headquartered in the U.S. The company received marketing approvals for their radioisotopes for the treatment of colorectal cancer, brain cancer, prostate cancer, breast cancer, pancreatic cancer, and ocular melanoma. The company generated 99.9% of their revenues from the U.S. It is an innovator in seed brachytherapy.
Mevion Medical Systems was incorporated in 2004 and has expertise in proton therapy for cancer treatment. The company is specialized in proton therapy solutions, single-room proton therapy, IMPT, compact proton therapy, and adaptive apertures. The company is based in the U.S. and has international offices in Japan, the UK, and a joint venture in China. The company invented compact proton therapy and is aiming to transform the cancer care by developing MEVION S250 series. These series are integration of their patented technology which delivers excellent beam quality with reduced system size & complexity, high reliability and less operational and capital cost.
Nordion, Inc. offers products and services for the diagnosis, prevention, and treatment of diseases. Its targeted therapies segment includes TheraSphere, a therapeutic medical device used for the treatment of inoperable primary and metastatic liver cancer. The company is a leader in the field of gamma technologies and medical isotopes. Additionally, the company also specializes in the field of radiopharmaceuticals, production irradiators, and health sciences. It also designs, constructs, installs, and maintains commercial gamma sterilization systems (used for sterilization of surgical apparatus). It has a presence in around 40 countries.
NTP Radioisotopes SOC Ltd. is a wholly owned subsidiary of South African Nuclear Energy Corporation (Necsa). The company is a leading supplier of radioisotope-based therapy products and diagnostic imaging worldwide. It has operational facilities in the near South Africa at Pelindaba nuclear facility. It supplies nearly one-third of the world’s Mo-99 and exports its products to around 50 countries. It produces and distributes other medical radioisotopes-such as, including iodine-131 and lutetium-177.
Curium was founded by the IBA Molecular and Mallinckrodt Nuclear Medicine Union in 2017 and is headquartered in the UK. The two companies are major North American and European suppliers. Curium is engaged in developing, manufacturing, and distributing high-quality radiopharmaceutical products to cater to patients across the globe. The company delivers vital products to over 14 million patients, including PET, SPECT, and therapeutic radiopharmaceuticals, every year. As of May 2021, the company had 957 employees.
Supply Side Estimates
Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.
Segment revenue determination via variable analysis and penetration modeling.
Competitive benchmarking to identify market leaders and their collective revenue shares.
Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.
Demand side estimates
Identifying parent markets and ancillary markets
Segment penetration analysis to obtain pertinent
revenue/volume
Heuristic forecasting with the help of subject matter experts
Forecasting via variable analysis
Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.
Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.
Understanding market estimates and forecasts (with the base year as 2022, historic information from 2018 to 2021, and forecast from 2023 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.
The report provides market value for the base year 2022 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.
The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.
We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.
All market estimates and forecasts have been validated through primary interviews with the key industry participants.
Inflation has not been accounted for to estimate and forecast the market.
Numbers may not add up due to rounding off.
Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).
Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).
Latin America includes Central American countries and the South American continent
Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.
GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.
We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:
Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.
Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.
The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."